IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer

IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer is a phase 3 interventional study registered as NCT07377643, led by Innovent Biopharmaceutical Technology (Hangzhou), and recruiting on the registry. Official title: A Randomised, Multicenter, Open-label Phase 3 Study to Compare IBI354 With or Without Pertuzumab vs. Taxane in Combination With Trastuzumab and Pertuzumab as First-line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Breast Cancer. Planned enrolment is 540 participants (estimated). The study started in 2026-02-10 and primary completion is expected in 2028-04-28. No results have been posted on ClinicalTrials.gov.